Case Report: Facial Erythema in an Elderly Man
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
Here is an interesting case published in JAMA Case reports of a man in his 80s with a pacemaker; a history of congestive heart failure, coronary artery disease, atrial fibrillation, transient ischemic attack, and Parkinson disease; and dependence in all activities of daily living presented to the dermatology department with a 4-month history of new-onset persistent facial eruption. He denied a history of facial flushing. The patient was initially treated for rosacea at an outside hospital with topical 1% metronidazole cream for 1 month without improvement and developed acute facial purpura after 1 day of treatment with oral doxycycline, which was discontinued. Because of the eruption’s rapid onset and violaceous appearance, as well as empirical treatment failure, the patient was referred for further evaluation. On examination, the patient had asymmetric, centrofacial, erythematous-violaceous indurated telangiectatic and ecchymotic plaques over a phymatous background (Figure, A). A series of punch biopsies were performed (Figure, B-D).

Microscopic examination findings revealed a dissecting vascular proliferation through the entire dermis. Ectatic vascular channels were lined by atypical plump endothelial cells (Figure, B and C). Immunohistochemistry staining results were negative for Human herpesvirus 8 (Figure, D). These findings were diagnostic of cutaneous angiosarcoma (CA).

Results of a positron emission tomography/computed tomography scan revealed only mildly avid malar subcutaneous thickening consistent with CA (American Joint Committee on Cancer tumor-node-metastasis staging T2aN0M0G2, stage IIB). When feasible, standard treatment entails surgery with or without radiation; however, owing to this patient’s comorbidities, poor performance status, and disease extent, reduced-dose intravenous paclitaxel (60 mg/m2) was initiated as palliative therapy. After completing 6 months of 120-mg paclitaxel weekly treatment, a partial response was obtained.

Source:https://jamanetwork.com/journals/jamadermatology/fullarticle/2763189
Like
Comment
Share